Associated Papers
Association of LRRK2 p.A419V with Parkinson's Disease in East Asians and analysis of age at onset.
Lim KS et al.
Npj Parkinson's Disease, 2026
A Complex FGF14 (TTC)/(TGC) Repeat Expansion in Parkinson's Disease.
Zheng X et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2025
Prevalence and Clinical Characteristics of the LRRK2 p.L1795F Variant in Central Europeans with Early-Onset and Familial Parkinson's Disease.
Ostrozovicova M et al.
Movement Disorders Clinical Practice, 2025
Exploring environmental modifiers of LRRK2-associated Parkinson's disease penetrance: An exposomics and metagenomics pilot study on household dust.
Talavera Andújar B et al.
Environment International, 2024
The p.Gly2019Ser is a common LRRK2 pathogenic variant among Egyptians with familial and sporadic Parkinson's disease.
William MB et al.
Npj Parkinson's Disease, 2024
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Westenberger A et al.
Brain : a Journal of Neurology, 2024
p.L1795F LRRK2 variant is a common cause of Parkinson's disease in Central Europe.
Ostrozovicova M et al.
Research Square, 2024
Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson's Disease.
Braunger LJ et al.
Journal of Parkinson's Disease, 2024
Autosomal dominant Parkinson's disease caused by the recently identified LRRK2 N1437D mutation in a Chinese family: Clinical features, imaging findings, and functional impact.
Sun YM et al.
Parkinsonism & Related Disorders, 2023
Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
Ito G et al.
Biomolecules, 2023
Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson's disease.
Turski P et al.
Frontiers in Neuroscience, 2022
Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.
Goveas L et al.
Cells, 2021
Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
Brockmann K et al.
Parkinsonism & Related Disorders, 2015
No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
Garcia-Miralles M et al.
Plos One, 2015
Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7.
Chia R et al.
Nature Communications, 2014
LRRK2 guides the actin cytoskeleton at growth cones together with ARHGEF7 and Tropomyosin 4.
Häbig K et al.
Biochimica Et Biophysica Acta, 2013
Genetic Screening of the Mitochondrial Rho GTPases MIRO1 and MIRO2 in Parkinson's Disease.
Anvret A et al.
The Open Neurology Journal, 2012
Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
Brockmann K et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2011
ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2.
Haebig K et al.
Plos One, 2010